NEUROSENSE THERAPEUTICS LTD(NASDAQ:NRSN) stock News

NRSN Latest News, Press Relases and Analysis

All

Press Releases

14 days ago - By: Neurosense

NeuroSense: PrimeC Produces Statistically Significant Reductions in Alzheimer's Disease Biomarkers

a month ago - By: Benzinga - Mentions: XRTX RNA KZIA APM ...

12 Health Care Stocks Moving In Thursday's Pre-Market Session

a month ago - By: Neurosense

NeuroSense's Drug Candidate Shows Early Signals of Benefit in Alzheimer's Patient-Derived Neurons

2 months ago - By: Neurosense

NeuroSense Therapeutics Announces $500,000 Private Placement at Premium to Market Price

a year ago - By: BusinessInsider

NRSN Stock Earnings: NeuroSense Therapeutics Misses EPS for Q1 2024

3 months ago - By: Neurosense

NeuroSense Provides Business Update and Progress for the First Half of 2025

3 months ago - By: Neurosense

Award-Winning Broadway, Television & Film Star Aaron Lazar Featuring NeuroSense CEO Alon Ben-Noon in a Special Live Podcast on ALS Science, PrimeC's Commercialization Strategies, and Community

5 months ago - By: Yahoo Finance - Mentions: GLP CRSP VRTX DHI ...

Why This Nano-Cap Stock Might Skyrocket To $14, Per Analyst Insights

5 months ago - By: Benzinga

Why This Nano-Cap Stock Might Skyrocket To $14, Per Analyst Insights

5 months ago - By: Yahoo Finance - Mentions: COIN MS HLT DB ...

Target downgraded, Wayfair upgraded: Wall Street's top analyst calls

6 months ago - By: Neurosense

NeuroSense Therapeutics Announces Successful Completion of Commercial Manufacturing Scale-Up for PrimeC in Preparation for Potential Canadian Market Launch

6 months ago - By: Neurosense

NeuroSense Therapeutics Releases Letter to Shareholders Outlining Clinical Progress, Regulatory Strategy, and Partnership Update

6 months ago - By: Neurosense

NeuroSense Therapeutics Announces Transformative Phase 2b MicroRNA Data, Highlighting PrimeC's Promise as a Disease-Modifying ALS Treatment

7 months ago - By: Neurosense

NeuroSense Therapeutics Reports Year End 2024 Financial Results and Provides Business Updates

7 months ago - By: Neurosense

NeuroSense Therapeutics to Present New Data from PrimeC's Phase 2b Trial in ALS at the Annual American Academy of Neurology Meeting

7 months ago - By: Market News Alerts

Market Alert: NeuroSense Therapeutics Advances Toward Early Canadian Commercialization of ALS Drug

7 months ago - By: PESG Research

PESG Releases Report on NeuroSense Therapeutics: Groundbreaking ALS Therapy Signals Massive Potential Opportunity in Billion Dollar Treatment Landscape

10 months ago - By: Neurosense

NeuroSense Therapeutics Enters Binding Term Sheet to Advance PrimeC for ALS

10 months ago - By: Neurosense

NeuroSense Provides Business Update and Third Quarter 2024 Financial Results

10 months ago - By: Neurosense

NeuroSense Receives Positive FDA Feedback on Phase 3 Study Design for PrimeC

11 months ago - By: Neurosense

NeuroSense Announces Completion of PARADIGM Study Highlighting PrimeC's Significant Efficacy and Survival Benefits in ALS

a year ago - By: Neurosense

NeuroSense Therapeutics Announces $5 Million Private Placement at Premium to Market Price

a year ago - By: Neurosense

NeuroSense Therapeutics to Participate in the 2024 International Symposium on ALS/MND

a year ago - By: Neurosense

New Analysis Shows PrimeC Significantly Improves Key miRNAs in ALS Patients

a year ago - By: Neurosense

NeuroSense Advances Plans for Early Commercialization of Groundbreaking ALS Treatment in Canada, Provides Further Updates

a year ago - By: Neurosense

NeuroSense Therapeutics Granted Key U.S. Patent for Novel PrimeC Formulation, its Lead Asset for ALS and Alzheimer's

a year ago - By: Neurosense

NeuroSense Regains Compliance with NASDAQ Minimum Bid Price Rule

a year ago - By: Neurosense

NeuroSense Therapeutics Announces Receipt of Nasdaq Minimum Bid Price Notification

a year ago - By: Neurosense

NeuroSense Therapeutics Announces Private Placement with Senior Management Participation at Premium to Market Price

a year ago - By: Neurosense

NeuroSense Therapeutics Announces Positive Biomarker Data from ALS Phase 2b Clinical Trial

a year ago - By: Neurosense

NeuroSense's PARADIGM ALS Clinical Trial Demonstrates Up to 73% Improved Complication-Free Survival Following Statistically Significant Slowing of Disease Progression

a year ago - By: InvestorPlace

NRSN Stock Earnings: NeuroSense Therapeutics Misses EPS for Q1 2024

a year ago - By: Neurosense

NEUROSENSE THERAPEUTICS LTD (NRSN) Stock News

NRSN Latest News, Press Relases and Analysis

NeuroSense: PrimeC Produces Statistically Significant Reductions in Alzheimer's Disease Biomarkers

12 Health Care Stocks Moving In Thursday's Pre-Market Session

NeuroSense's Drug Candidate Shows Early Signals of Benefit in Alzheimer's Patient-Derived Neurons

NeuroSense Therapeutics Announces $500,000 Private Placement at Premium to Market Price

NRSN Stock Earnings: NeuroSense Therapeutics Misses EPS for Q1 2024

NeuroSense Provides Business Update and Progress for the First Half of 2025

Award-Winning Broadway, Television & Film Star Aaron Lazar Featuring NeuroSense CEO Alon Ben-Noon in a Special Live Podcast on ALS Science, PrimeC's Commercialization Strategies, and Community

Why This Nano-Cap Stock Might Skyrocket To $14, Per Analyst Insights

Why This Nano-Cap Stock Might Skyrocket To $14, Per Analyst Insights

Target downgraded, Wayfair upgraded: Wall Street's top analyst calls

NeuroSense Therapeutics Announces Successful Completion of Commercial Manufacturing Scale-Up for PrimeC in Preparation for Potential Canadian Market Launch

NeuroSense Therapeutics Releases Letter to Shareholders Outlining Clinical Progress, Regulatory Strategy, and Partnership Update

NeuroSense Therapeutics Announces Transformative Phase 2b MicroRNA Data, Highlighting PrimeC's Promise as a Disease-Modifying ALS Treatment

NeuroSense Therapeutics Reports Year End 2024 Financial Results and Provides Business Updates

NeuroSense Therapeutics to Present New Data from PrimeC's Phase 2b Trial in ALS at the Annual American Academy of Neurology Meeting

Market Alert: NeuroSense Therapeutics Advances Toward Early Canadian Commercialization of ALS Drug

PESG Releases Report on NeuroSense Therapeutics: Groundbreaking ALS Therapy Signals Massive Potential Opportunity in Billion Dollar Treatment Landscape

NeuroSense Therapeutics Enters Binding Term Sheet to Advance PrimeC for ALS

NeuroSense Provides Business Update and Third Quarter 2024 Financial Results

NeuroSense Receives Positive FDA Feedback on Phase 3 Study Design for PrimeC

NeuroSense Announces Completion of PARADIGM Study Highlighting PrimeC's Significant Efficacy and Survival Benefits in ALS

NeuroSense Therapeutics Announces $5 Million Private Placement at Premium to Market Price

NeuroSense Therapeutics to Participate in the 2024 International Symposium on ALS/MND

New Analysis Shows PrimeC Significantly Improves Key miRNAs in ALS Patients

NeuroSense Advances Plans for Early Commercialization of Groundbreaking ALS Treatment in Canada, Provides Further Updates

NeuroSense Therapeutics Granted Key U.S. Patent for Novel PrimeC Formulation, its Lead Asset for ALS and Alzheimer's

NeuroSense Regains Compliance with NASDAQ Minimum Bid Price Rule

NeuroSense Therapeutics Announces Receipt of Nasdaq Minimum Bid Price Notification

NeuroSense Therapeutics Announces Private Placement with Senior Management Participation at Premium to Market Price

NeuroSense Therapeutics Announces Positive Biomarker Data from ALS Phase 2b Clinical Trial

NeuroSense's PARADIGM ALS Clinical Trial Demonstrates Up to 73% Improved Complication-Free Survival Following Statistically Significant Slowing of Disease Progression

NRSN Stock Earnings: NeuroSense Therapeutics Misses EPS for Q1 2024

NeuroSense Receives Delisting Notice from Nasdaq and Intends to Appeal